Mahdi, Soheil
Ronzano, Nadia
Knüppel, Ane
Dias, José Carlos
Albdah, Ayman
Chien-Ho, Lin
Almodayfer, Omar
Bluschke, Annet
Karande, Sunil
Huang, Huei-Lin
Christiansen, Hanna
Granlund, Mats
de Vries, Petrus J.
Coghill, David
Tannock, Rosemary
Rohde, Luis
Bölte, Sven http://orcid.org/0000-0002-4579-4970
Funding for this research was provided by:
Swedish Research Council
Forskningsrådet om Hälsa, Arbetsliv och Välfärd
Forskningsrådet FORMAS
VINNOVA (259-2012-24)
National Cheng Kung University
Article History
Received: 8 May 2017
Accepted: 9 February 2018
First Online: 17 February 2018
Compliance with ethical standards
:
: Soheil Mahdi declares no conflict of interest related to this work. Nadia Ronzano declares no conflict of interest related to this work. Ane Knüppel declares no conflict of interest related to this work. José Carlos Dias declares no conflict of interest related to this work. Ayman Albdah declares no conflict of interest related to this work. Lin Chien-Ho declares no conflict of interest related to this work. Omar Almodayfer declares no conflict of interest related to this work. Annet Bluschke declares no conflict of interest related to this work. Sunil Karande declares no conflict of interest related to this work. Huei-Lin Huang declares no conflict of interest related to this work. Hanna Christiansen declares no conflict of interest related to this work. Mats Granlund declares no conflict of interest related to this work. Petrus J de Vries reports no direct conflicts of interest related to this article. He has been a study steering group member of three international multi-centre trials of mTOR inhibitors in Tuberous Sclerosis Complex (TSC) sponsored by Novartis and has been co-PI of phase II clinical trials part-sponsored by Novartis. David Coghill reports grants and personal fees from Shire, personal fees from Janssen-Cilag, personal fees from Lilly, grants and personal fees from Vifor, personal fees from Novartis, personal fees from Medice, personal fees from Oxford University Press, outside the submitted work. Rosemary Tannock reports honorarium and travel costs for unrestricted talks sponsored by Shire, Lilly, Medice and Research support from Cogmed (provided software at no cost for my federally funded research studies on working memory training). Luis A. Rohde received grant or research support, and served as a consultant or in the speakers’ bureau of Eli Lilly and Co., Janssen, Medice, Novartis and Shire. The ADHD and Juvenile Bipolar Disorder Outpatient Programs chaired by Dr. Rohde received unrestricted educational and research support from the following pharmaceutical companies: Janssen, Novartis, and Shire. Dr. Rohde received travel grants from Shire to take part in the 2015 WFADHD congress. He received royalties from Artmed Editora and Oxford University Press. Sven Bölte reports no direct conflict of interest related to this article. Dr. Bölte discloses that he has in the last 5 years acted as an author, consultant or lecturer for Shire, Medice, Roche, Eli Lilly, Prima Psychiatry, GLGroup, System Analytic, Kompetento, Expo Medica, and Prophase. He receives royalties for text books and diagnostic tools from Huber/Hogrefe, Kohlhammer and UTB.